ELGAN (22-28SA)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which ELGAN (22-28SA) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT07273643

Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With…

This study aims to understand the role of extracellular vesicles (EVs) in extremely premature infants, those born before 28 weeks of gestation. EVs are tiny par…

France30 participantsStarted 2026-01-13

Treatment: Venous Cord blood sample, Arterial cord blood sample

All recent trials (3 shown)

Not Yet RecruitingPhase 2

NCT07058025

Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants

This clinical trial aims to evaluate the safety and efficacy of mesenchymal stromal cell (MSC) therapy in extreme preterm infants to prevent bronchopulmonary dy…

Canada168 participantsStarted 2025-10-01

Treatment: Human Allogenic Umbilical Cord Mesenchymal Stromal Cells, Sham procedure control

Not Yet RecruitingNot Applicable

NCT06737965

Cardiovascular Immaturity in Extremely Low Gestational Age Newborns: a Fundamental Prospective Study

Birth is a major turning point in the life of the newborn, as it moves from intrauterine life to extrauterine life. This sudden transition forces the newborn to…

France15 participantsStarted 2025-01-01

Treatment: Medical abortion, Foetopathology exam